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ABSTRACT
Previous research has consistently highlighted the importance of
stakeholder engagement in identifying and developing solutions to
ethical challenges in genomic research, especially in Africa where
such research is relatively new. In this paper, we examine what
constitutes good ethical practice in research, from the perspectives
of genomic research participants in Uganda. Our study was part of
a multi-site qualitative study exploring these issues in Uganda,
Ghana and Zambia. We purposively sampled various stakeholders
including genomic research participants, researchers, research
ethics committee members, policy makers and community
members. This paper presents the ﬁndings from in-depth
interviews with 27 people with diabetes who had participated in a
diabetes genomic study. Data were collected using semi-structured
interviews. Manual thematic content analysis was conducted using
a framework approach. Findings indicate three key requirements
that research participants see as vital for genomic research to be
more responsive to research participants’ needs and contextual
realities: (1) de-emphasising the role of experts and institutions in
the consenting process, (2) clarity about the timing and nature of
feedback both of ﬁndings relevant to the health of individuals and
about the broad progress of the study, and (3) more eﬀective
support for research participants during and after the study.
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Background
Genomic research raises key ethical challenges related to consent, privacy, ownership of
samples and data sharing (Cambon-Thomsen, Rial-Sebbag, & Knoppers, 2007). Ques-
tions have also been raised about how to explain key scientiﬁc concepts in lay terms
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to improve research understanding (de Vries et al., 2011; Nyika, 2009; Tindana et al.,
2012; Upshur, Lavery, & Tindana, 2007; Wonkam, Kenfack, Muna, & Ouwe-Missi-
Oukem-Boyer, 2011). Several studies have emphasised the importance of community
engagement as a means of facilitating participants’ understanding of the research
(Ahmed & Palermo, 2010; Boutin-Foster et al., 2008). However, there is a dearth of
empirical evidence particularly from the African continent that explores these and
related challenges (Munung et al., 2015). For instance, it has been observed that what
constitutes an eﬀective community engagement model when conducting genomic
research in Africa remains unclear (Tindana et al., 2015). The development of such a
model necessarily requires eliciting the views of genomic research participants in the
African context. Similarly, how best to explain key concepts in genomic research – for
instance, those relating to data and sample sharing – may also require the input of a
range of stakeholders. In addition, there is evidence that the challenge of making
these concepts easily understood by research participants might also be compounded
by some clinical research practices that appear to be common in some settings. For
instance, a study conducted in North America revealed that only a small number of clini-
cal researchers incorporate information about data sharing in their informed consent
forms, because data sharing is not their responsibility (McGuire, Hamilton, Lunstroth,
McCullough, & Goldman, 2008). There is a need to investigate the potential for this
kind of issue to arise in the African setting, and to suggest mechanisms for ensuring
awareness of the need for the inclusion of all essential information in consent
documents.
Considering these gaps, researchers have highlighted the need to develop novel
approaches to the informed consent process in the African context (Munung
et al., 2015; Wright, Koornhof, Adeyemo, & Tiﬃn, 2013), and as some have noted
such eﬀorts would ideally incorporate input from multiple stakeholders including
genomic research participants (Munung et al., 2015). The need to explore these
approaches is particularly compelling in the case of Africa where genomic research
is relatively new. A particularly important ethical issue identiﬁed in the literature has
concerned whether researchers have a responsibility to feedback ﬁndings to partici-
pant, and if so what the nature and scope of those responsibilities might be (Johnson
& Gehlert, 2014; Marsh et al., 2013). Carrieri et al. (2016) point out that partici-
pants’ preferences in relation to receipt of primary and incidental ﬁndings will
diﬀer from person to person and over time, and that caution needs to be exercised
to avoid universal consent models that are insensitive to peculiarities of a given
setting. While feedback of results remains a global issue, further research in
Africa is particularly important given the rapid growth of genomic research on
the continent compounded by factors such as low literacy, and cultural values and
beliefs.
In this paper, we present the ﬁndings of a study we conducted to inform the develop-
ment of a robust and supportive ethical and governance framework for genomic research
in Africa. Our purpose in this research was to explore perspectives on good ethical practice
in the conduct of genomic research from the point of view of those who have participated
in a genomic study in Uganda.
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Methods
Study design
We conducted a multi-site qualitative study in Uganda, Ghana and Zambia. At the
Ugandan site, we purposively selected 27 individuals from a group of patients attending
the same diabetes clinic and who had participated in a previous diabetes genomic
study. These were carefully selected to ensure that only those who had participated in a
genomic study at least six months earlier and, therefore, with suﬃcient experience of
genomic research participation to draw upon were interviewed. The other stakeholders
included two members of a research ethics committee (one of whom was a community
advisory board member), six researchers and their team members (including four
medical doctors, a research nurse and a counsellor), one policy maker, four community
leaders (including two oﬃcials of the local administration system and two religious
leaders) and ﬁve non-participants. Using semi-structured topic guides, in-depth inter-
views were conducted with these participants. This paper is based exclusively on data
from interviews with 27 participants from the Ugandan site who had participated in a
genomic study.
Data management and analysis
All the interviews were voice-recorded – following consent from the interviewees – and
transcribed. The interviews we used for the analysis presented in this paper were con-
ducted in Luganda and were simultaneously transcribed and translated into English by
trained translators. Manual thematic content analysis was conducted using a framework
approach (Gale, Heath, Cameron, Rashid, & Redwood, 2013). This approach allows for
the in-depth investigation of qualitative data by combining both case and theme-based
analytical strategies (Smith & Firth, 2011). We used the framework approach because it
is well suited for analysis involving multiple researchers and sites, as the case was with
this study. The approach was particularly useful for our analysis as it provides a structure
that facilitates a transparent process of analysing data by case and by code (Gale et al.,
2013).
Ethical approval for this study was obtained from the Uganda Virus Research Institute
Research Ethics Committee (SS 3856), and from Oxford University (OxTREC Reference:
580-16). All interviewees were assigned a unique identiﬁer (an ID number) which was
used on all transcripts. Real personal names and names of places of work or residence
were not included in any transcripts. A database linking real names and ID numbers
was stored securely and separately from the data and is accessible only to the PIs.
Findings
Reﬂecting on their experiences as participants in a previous genomic study on diabetes,
which was complemented by a number of clinical tests – discussed in more details
below – our interviewees highlighted a number of research practices that they felt could
be improved upon and suggested new ones that could be adopted as a way of making
research more responsive to the participants’ needs and contextual realities. Their perspec-
tives were wide-ranging, touching on participant recruitment and consenting practices,
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the conduct of the study and participant expectations from researchers, and what happens
when the study ends. Our analysis suggested three particularly important themes: (1)
information delivery and the consenting process, (2) feedback to research participants
and (3) support during and after the study.
1. Information delivery and the consenting process
One of the key areas of concern for research participants was how information about
the genomic project was delivered to them, and how informed their consent was for par-
ticipating in the research. When asked about the genomic study in which they had partici-
pated 6–12 months back, 11 of the 27 participants initially reported that they were not
aware that they had participated in any such study, implying that they thought procedures
they went through – such as blood draws – were part of routine care at the hospital. On
further reﬂection, interviewees did recall their research participation and the consent
process. However, while they remembered they had participated in the study they also
indicated that they had agreed to participate without a full and complete understanding
of what this participation entailed. While less than perfectly informed consent may not
necessarily be unique to genomic studies, it was clear that in this study a signiﬁcant
factor in this was the diﬃculty which participants found in understanding genomic
research, as illustrated by the inaccuracies that were evident in their perceptions of
genomic concepts. It is important to note that inadequately informed consent does not
necessarily imply researchers’ failure to convey the study information fully to the partici-
pants. It was apparent in our interviews that participants did not seek clariﬁcation on
issues or ask questions even when they were given ample opportunity (we return to this
issue in more detail later), or they might have not fully grasped genomic concepts even
after the researchers made eﬀorts to explain these. Other explanations are that the partici-
pants possibly had forgotten about the study due to passage of time, or might have not
been telling us the whole truth.
When asked how these information and consent challenges might be overcome, partici-
pants identiﬁed speciﬁc standard procedures that they felt would constitute good research
practice. One such procedure related to delivery of study information to prospective par-
ticipants. An issue of particular interest to participants was the context in which the study
information is delivered and who should deliver the information. Participants highlighted
the need for researchers to reach out to prospective participants within a community –
rather than a health facility – context. They proposed that such delivery of study infor-
mation involve community members as principal players, as presented in more detail later.
Our analysis yielded three key explanations for the choice of community as the context
for information delivery and for engaging community members. First, it was thought that
the community context would provide an environment for free interaction between
researchers and prospective participants, where the latter would feel less inhibited to
ask questions or raise concerns. This is especially so when individuals with whom commu-
nity members identify are engaged in the information delivery eﬀort. Such an environment
contrasts sharply with that in a health facility context where power dynamics between the
researcher/health worker and the participant/patient might inﬂuence information
exchange and comprehension. The inﬂuence of this power relationship was evident in
the perspectives of diﬀerent participants on the power and authority of health workers.
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For some of these, asking a health worker for clariﬁcation amounted to challenging the
authority of the health worker, as illustrated in an excerpt from an interview with Research
Participant 26:
Interviewer: Now, when you see these blood samples being drawn from your body; how do
you understand that?
Participant: I don’t understand it… .
Interviewer: At times you have to ask. Now when they are bleeding and you do not ask,
what are you up to?!
Participant: Ahh… , to ask a musawo [health worker] such a question! It is hard!
Similarly, advising a researcher/health worker on good practice in research was considered
by some as a redundant exercise since these are trusted experts in their subject area, as
echoed during an interview with Research Participant 20:
Interviewer: So what advice would you give us [on good practice in genomic research]?
Participant: My friend, what idea to give you; to such learned ones.… [laughing a bit].
Interviewer: Oh yes! You can also have an idea to give us about anything… . What advice
would you give us?
Participant: The learned ones know how to handle their work with their experience. I
cannot give any idea … and they know better how to handle everything.
The fact that participants’ perception of unequal power relations between health worker
and patient undermines their ability to ask questions and make suggestions may indicate
that a health facility is a less-than-ideal context for obtaining informed consent, particu-
larly when the researcher/health worker is the one interfacing with the prospective partici-
pant/patient in the consenting process. Notably, this may still be true when the researcher/
health worker has made every eﬀort to fully inform the participant about the study.
Indeed, it was evident in the above excerpts that the unequal power relationship
between the researcher and the participant partly explains why participants in this
study initially reported that they were not aware of their participation in the study – or
indeed any study – and whose understanding and awareness was rather superﬁcial once
they had recollected their participation.
Interviewer: Can you please tell me about the genomic research project you participated in?
Participant: The research that I joined, we came here to the diabetes clinic and the medical
staﬀ explained to us that there is research that was going to start here to ﬁnd
out why diabetes is so rampant so as to ﬁnd the drug for us.
Interviewer: Is that all that you were told; did they mention about genomic research?
Participant: The way they asked us the questions, was leading to genomic issues. Because
they used to ask about my parents… .
Second, participants preferred their community as the context for information delivery
because it was not enough to target only prospective research participants in delivering
the study information. Based on these views, good ethical practice entailed an obligation
not just to the participants but to the entire community from which the participants are
drawn. The participants held the view that a new research project should serve as an
opportunity for both the prospective participants and the entire community to learn
about the health condition under study, and to be able to use this knowledge to take pre-
ventive or remedial action. Reﬂecting on the ideal strategy for information delivery about
the study, one participant observed:
GLOBAL BIOETHICS 5
[Information delivery] would be like collecting people in the community and teaching them,
examining them, bleeding them for samples and conducting sessions for all the people in the
community to be informed about diabetes. Even those who have not acquired the disease, to
be aware of it… . For example, you mobilise the community using the loud speakers, advis-
ing them to converge at Freedom City [mall] like they do for Agriculture and Veterinary.
(Research Participant 09)
Third, participants preferred community members – rather than “experts” – as agents for
information delivery because these were accessible both in terms of physical proximity,
and fellow community members being able to identify with them and more likely under-
stand and trust them. Community members were therefore believed to be more effective in
articulating information about research in the community. According to the participants,
these community members – who would preferably include ofﬁcials from different entities
such as local councils and community-based organisations, as well as religious leaders,
women leaders and family heads – should constitute village committees in charge of infor-
mation delivery. In suggesting this, participants seemed to highlight the importance of
using the existing grassroots structures, including local government (Local Councils),
and opinion leadership. As the following excerpt illustrates, some of them appeared to
suggest that in the event of a new study, community members could be identiﬁed and sen-
sitised about the proposed study, so that these can in turn play an instrumental role in the
delivery of study information.
I think even at the village level, there should be the committee that would teach the grassroots
people so that they also get well informed. So the committee would start from the village level
or parish level. Because they [community members] deliver the information very well to the
grassroots people. But when we have committees at the top, at the higher level … the infor-
mation remains there; it does not reach the grassroots people. … (Research Participant 04)
It is noteworthy that this participant echoes a proposal, highlighted earlier, for infor-
mation delivery efforts that target the broader community rather than only prospective
participants. But study participants also identiﬁed some personal strengths or character-
istics of community members that they considered ideal for the role of information deliv-
ery, while noting the need to build on these strengths by training them so they are in a
better position to perform this role and also handle those in the community who are in
need of help.
Religious leaders are very good at counselling, then the teachers, [they] pass on the infor-
mation [easily] to others … then elders and mothers … in the community, they are more
recognised and trusted. (Research Participant 08)
Community leaders should be trained in how to handle and sensitise their people. To reach
that point they will have studied what should be done like how to handle HIV/AIDS patients.
(Research Participant 01)
A rather diﬀerent but related issue was the ongoing need for information and other
forms of support to participants during the study. Against the background of having con-
sented to participate with insuﬃcient understanding of the study, some participants
expressed concerns about unmet informational and emotional support needs during
their participation. They looked to this support as a means of plugging the outstanding
information gaps in their knowledge of the study they were participating in. For these par-
ticipants, good ethical practice in this kind of research would require that researchers
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maintain regular dialogue with their participants, so the latter can gain a full understand-
ing of the study. Regular dialogue would also comfort and assure the participants to allay
some of their worries, including that their samples would be used for the purposes for
which they were expressly intended.
[My advice would be that] when you draw the samples from us, you continue teaching and
counselling us that “do not get worried, we are going to test this blood.” But we left there
when we had not yet understood anything; I didn’t understand anything… . I would
suggest that when you come to us, you sensitize us about the issue… . Like for this blood
that was bled from us recently, we remained wondering at that much blood they drew
from us. So they took our blood and we said “what to do?” So we came back home just
like that… . (Research Participant 27)
Yet other participants proposed ongoing information not because they were insufﬁciently
informed when consenting to participate in the study, but because they wanted to be gen-
erally updated on new developments pertaining to their health condition, such as new
therapies or dose prescriptions.
The recommendation I am giving is just to keep in touch with the patients [who donated
samples]; whatever new thing that you discover, [you need] to keep us informed… . Yes,
to keep in touch [with your patients], at least calling them, or if there are any changes, to
give them the feedback. (Research Participant 19)
2. Feedback to research participants
The second major theme arising out of the analysis of our interviews with participants,
concerned the issue of feedback of results from both the study itself and the other, clinical,
tests they were oﬀered at the time of recruitment. The range of tests oﬀered was signiﬁcant,
as is clear from this extract from the project’s participant information sheet.
The tests on your blood will include those that look for diabetes, possible anaemia, high
cholesterol and to see how well your kidneys and liver are working. We will also test for infec-
tious diseases like HIV… .. If you wish, you can choose to receive some of your test results
… . The results you can choose to collect are: HIV results, haemoglobin, HbA1C, Fasting
plasma glucose, BMI and blood pressure. We will not provide the results of those tests
related to your genes. This is because scientists do not yet fully understand the role of
these genes in disease, and so the information may not be directly useful to you.
When our interviewees raised concerns about feedback this tended to take two forms:
concern about delays and lack of clarity about timing, and views about how the feedback
of information deemed sensitive should be handled. With regard to the ﬁrst of these,
several participants expressed disappointment over the perceived delay in receiving
their results. Some seemed to speculate that the reason why the results were not being
returned was that the researchers thought that participants were too scared of the possi-
bility of the results indicating a serious health condition.
I for one, I need my data [results] … . I will not fear anything, be it HIV… . So there is
nothing to fear – the more you fear, the more you are sabotaging your own life… . What
I feel much concerned about is to get my results… . (Research Participant 02)
Participants narrated their experiences of delayed results, and what the delay meant to
them. For the majority, they considered that delayed results meant that they were not
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able to effectively track the progress of their illness and make informed decisions around
lifestyle adjustments and the right medication and dosage, given their health condition
and its gravity.
My issue is, I want to know my results, let them tell me what type of Diabetes I have so that I
get the medicine that can sustain me well, because they will have tested my blood well… .
[Researchers need to] inform each participant about research results [in order to answer
questions such as] “In what group of diabetes is that person”? I’m so much concerned
about that. (Research Participant 09)
Give us the results so that we get to know whether diabetes [blood sugar] has reduced. Tell us
where you have reached so far. In case of any change in my health, [the knowledge of my
results] would ease follow up to improve my health… . (Research Participant 10)
For others, the implication of delayed results was more serious, in that the longer it took to
get their results back, the closer they got to a point at which it would be too late to beneﬁt
from the available therapy.
I happen to think about the blood sample results that have really taken long. When shall we
ever know the results? Could be by that time some of us will have already died! (Research
Participant 13)
Yet for the other participants, getting their results back and on time seemed to be the
minimum expectation from their voluntary participation in the study. These implied
that it was their right to be informed about their results given what some perceived as
the sacriﬁce they made in offering their blood sample.
The issue [I would like to stress] is to give us the results… . Let them show us the results… ,
explain to us where to go for treatment, what drug to use. It is so hurtful when you have
participated in the research and you don’t get the outcome of the research. (Research Partici-
pant 08)
Research Participant 11 did not express anticipation of results from researchers but only
suggested the researchers’ return of the results was the correct thing to do:
You [the researchers] have our phone numbers. You can always call us back at any time when
you need us, because we would also wish to know the outcome.
We infer based on these participants’ narratives that good ethical practice on the part of
the researcher calls for a clearly laid out framework for the return of individualised
research results, especially if the results contain information with major implications
for the participant’s health. In this particular study, the questions of feedback related to
the clinical tests offered complementary to the genomic research – it was clear that
there would be no feedback of genomic ﬁndings. However, our ﬁndings do suggest
both, on the one hand that when feedback of any kind is offered it is vital that there is
clarity about what can be expected and that these expectations are in fact met. And, on
the other hand, that there is a broad expectation that clinically useful information
should be fed back. Participants seemed unaware of the fact that genetic results might
sometimes fall into this category, but the broad implication of their comments is that
careful consideration ought to be given to feedback within research studies taking place
in the clinical setting.
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It is noteworthy that the perspectives on feedback presented above, relate primarily to
individualised rather than generic feedback i.e. to feedback relevant to the participant’s
own health. In addition to this, however, some participants expressed an interest in
more general feedback about the progress of the research and about its ﬁndings is an
important aspect of the researchers’ responsibility to participants and communities.
This was expressed by Research Participant 18 who did not indicate the expectation of
researchers returning his test results but did highlight the importance of generic feedback
when prompted to suggest how better genomic research can be conducted and managed:
“because you took our blood samples, you should always call us back as the witnesses of
the research.” The same participant went on to suggest the institutionalisation of the
researchers’ return of results to participants:
Interviewer: In your view, should there be speciﬁc policies governing genomic research?
Participant: Yes.
Interviewer: What are your views?
Participant: Like teaching us, even telling us what they have found in our blood, and
keeping us updated.
The other aspect concerning the issue of feedback was the question of how to deliver
sensitive results. Participants discussed potential sensitivities about the results generated
from their samples, and the way they are fed back to sample donors. It appeared from
our data that they were more particularly concerned about incidental results that were
not necessarily related to the original purpose of the tests. They noted the likely family
fallout that could ensue if caution was not taken in the delivery of such feedback. In the
light of these concerns, our ﬁndings suggest that participants did not take for granted
the researchers’ commitment to conﬁdentiality as spelt out in the study information
sheets. For these participants, good ethical practice in the provision of feedback therefore
necessitated the strict upholding of conﬁdentiality but also a clearly laid out procedure for
disclosure of sensitive results to third parties if the participant, not the researcher,
approved of this.
It [result] should be conﬁdential, in case it is found out that it is such a scaring illness that
could scare the husband, so as not to disclose to him. Or else … counsel the husband
seriously then disclose to him otherwise this can easily break the marriage. For example
we have come to participate in the research about diabetes, then the test shows that there
is HIV as well. Let them tell you [sample donor] ﬁrst, [followed by] serious counselling
before calling the husband … because I have come alone and I was invited as [sample
donor] but not as Mrs. so and so. (Research Participant 08)
3. Support during and after the study
Reﬂecting on their experience of participating in a previous genomic study, a signiﬁcant
number of participants cited insuﬃcient or lack of support from the researchers as a key
issue that needed to be addressed. These sentiments were reiterated during a dissemina-
tion event for the research participants: during question time, most of the concerns and
questions raised by the participants were to do with the perceived gaps in diabetes care
and the urgent need for help in addressing these. We view this as an ethical challenge per-
taining to the conventional practice of clinical research in general, not just genomic
research.
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There were several aspects to the perceived insuﬃcient or lack of support from the
researchers. For a minority, it was about the compensation they received for participating
in the study, which they considered less than they deserved. Some of them interpreted this
as a lack of recognition of their generosity in donating their samples for research.
My issue in this research is, we are given very little money for transport, plus feeding, at least
they would give us 30,000/= otherwise 15000/= was so little [given that] one would be bled for
6 vacutainers of blood sample… . For a person to consent for a genomic study, and donate
samples for the research! (Research Participant 11)
In case this blood sample has helped you and when you still have the participant in your
records, then you would be considerate and give a token to those that participated in the
research… . (Research Participant 10)
For other participants, the concern was about the absence of support for participants who
could no longer travel to health facilities to obtain care due to a deterioration in their
health. They argued that it was premature for the researcher-participant relationship to
end once samples were drawn. In this case, good ethical practice according to these par-
ticipants required sustained contact between the researcher and the participant/patient.
For some, sustained contact would particularly include home visitations to follow up on
former participants.
I would suggest that there be a policy to go to sick people’s homes to ﬁnd more about their
genomic health; for those who cannot come here to the hospital for treatment or examin-
ation… . I suggest that it be an ethical requirement to] have people who are responsible
for the [outreach] exercise. (Research Participant 23)
[We prefer that] researchers do not neglect us patients; like now we have joined the research,
and after a while we do not hear about the research any more. When they have already taken
our blood samples and thereafter we lose the follow up. So let this contact continue; this
would be so helpful to us. (Research Participant 22)
A more frequently raised concern about support to research participants related to pre-
scription drug procurement. Participants narrated the diﬃculties they encountered in
ensuring that they had a constant supply of the required prescription drugs, because of
the prohibitive cost of the drugs. These participants were unequivocal in their appeal
for help in procuring the drugs either by way of full ﬁnancial cover or discounted prices.
My recommendation would be to reduce drug prices or to go about it like they did for HIV/
AIDS [i.e. free ART]. At least when the drug is at a reasonable price. Now this [diabetes] drug
is for one month, when you add the consultation fee, plus this Shillings90,000/= that I pay
when I come every month, where to get the money then?! (Research Participant 14)
We are charged a lot of money! And when we are seated [in the doctor’s waiting room] with
other patients you can hear some of them expressing similar sentiments. One of them noted:
“I will not report this other health problem because if I do so they will write more drugs, when
I do not have the money, and that will make me worry so much which may worsen my health
condition.” Sincerely you notice some people who cannot aﬀord just die so fast. So I would
appeal to be helped like it is done for HIV patients who are given free drugs. (Research Par-
ticipant 01)
But the excerpt from the interview with Research Participant 01 above also highlights
the complexity of inaccessible prescription drugs. As the participant suggests, the
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prohibitive cost of drugs did not just make it diﬃcult for patients to access prescription
reﬁlls for the treatment of a known condition. By causing the patients to refrain from
revealing to the health worker new developments in their health condition for fear that
this would otherwise lead to an additional prescription for which they were not able to
pay, high drug costs also undermined patients’ full disclosure of health status.
Some of the participants lamented that they did not deserve the experience of not being
in a position to procure the prescribed drugs given their advanced age and the substantial
amount of money and time they had invested over the years in the facilities where they
sought healthcare.
I have already told you that we, the aged ones, no longer have money to buy the drug. There
could be an arrangement for us to be supported with the drug or to reduce the prices of the
drug; we have really spent long here and we have put in a lot of money at this hospital for the
treatment. Right now when you do not come with Shillings150,000/= to 200,000/= you
cannot get the drug to sustain you for a month!… . Like for me I have many illnesses; arthri-
tis, ENT problem, Ulcers, Diabetes, hypertension … . That is the biggest problem for us the
aged ones, and you cannot do anything for income generation. We have to feed, we do not
have any support and our children have their own problems and responsibilities. (Research
Participant 15)
Musawo [health worker], my appeal is to be helped with some reasonable amount of drug
covering like a month or two to sustain us, but they give us very little drug and tell us to
come back in a month when we do not have money. The drug is quite expensive! (Research
Participant 27)
Others suggested that they deserved support from researchers because of their volun-
tary participation in the study. They noted that they could beneﬁt from trial drugs, but also
from associated support – such as food assistance. Such support, according to the partici-
pants, would facilitate proper day-to-day management of their medication for minimising
its negative eﬀects and enhancing their quality of life.
There is one issue I would like to talk about: the researchers should make a drug and give us
as they try it while carrying out the research.… they give you the drug and draw samples
from your body for the ﬁrst time, then afterwards they come back and check to see
whether the drug is eﬀective or not, or even to help us… some of us do not have any
help from anywhere. The diabetes drug is so expensive, at least when you participate in
the research and you are given the drug it can sustain you for a while … . Because at
times when they go back to the participants they ﬁnd the participants have already died
… and at times some die just because they cannot aﬀord the drug. That is why it is said
that diabetes is for rich people … . [Also] biologically the drug we swallow can be poisonous
in our body when you do not eat the food that can dilute the drug. Yet this food is so expens-
ive, so they should support us so as to live longer to sustain our children till the time when we
leave this world. (Research Participant 26)
[We would appreciate] if the researchers could help us and give us the drug … or get us
items for use as we the diabetic participants. (Research Participant 18)
Discussion
In this paper, we explore perspectives on good ethical practice in the conduct of genomic
research from the point of view of those who have been involved as research participants
in a genomic study in an African clinical context. Our analysis suggests the importance of
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three themes: (1) information delivery & the consenting process, (2) the need for clarity
about what feedback can be expected and when and (3) support during and after the
study. These ﬁndings suggest some enduring gaps in clinical research ethics in general
but also more particularly in genomics and the need for further engagement and research
on these issues. It was clear, for example, that the question as to how best to obtain ade-
quately informed consent for genomic research in low literacy settings remains an impor-
tant and unresolved challenge. In addressing this question, ﬁndings from previous studies
in other countries (de Vries et al., 2011; Emerson, Singer, & Upshur, 2011; Tekola et al.,
2009; Tindana et al., 2012; Tindana et al., 2015) have highlighted the importance of com-
munity engagement as a means of identifying processes that are culturally acceptable and
that enhance prospective participants’ understanding of the study. Our study builds on
this evidence base by shedding some light on Ugandan participants’ perspectives particu-
larly on who should be involved in obtaining consent, and in which kinds of contexts the
consent should be sought. Findings from this study point to the need to de-emphasise the
role of experts (doctors and other health workers) and institutions (health facilities), and
to instead principally engage community members and spaces as a means of obtaining
adequately informed consent for research participation. Indeed, our ﬁndings suggest
that, on reﬂection, our interviewees felt that they had consented to participate without ade-
quate information about the study, which echoes ﬁndings from several previous studies
(Robinson, Slashinski, Wang, Hilsenbeck, & McGuire, 2013; Traore et al., 2015).
In addition, the ongoing need for information and other forms of support to partici-
pants during the study – which was expressed by those who reported having not been ade-
quately informed about the genomic study they had participated in – raises another
important question: should information delivery be a one-oﬀ exercise to be conducted
at the time of participant recruitment, or should it be a process that spans both the par-
ticipant recruitment and study implementation phases? Our ﬁndings suggest participants’
view that in the same way that ideal consent has been viewed as a process (Kaye et al.,
2015; Stein & Terry, 2013), study information delivery ought to be treated as a process
in which researchers continue to interface regularly with participants to, among other
things, clarify or reaﬃrm the study information already delivered and assure participants
about the honesty and well-meaning intensions of the researchers. Study information
delivery could therefore be viewed as ideally a process for building trust through establish-
ing a long-term relationship between the researcher and participants.
Our ﬁndings suggest that the current, conventional ethical standards and practices may
not be suﬃciently responsive to participant and community concerns and interests in
addressing the complexity of the ethical challenges in research. A good example of this
is the expectations expressed by our interviewees about feedback of information to
them personally and about the progress of the project more generally. Firstly, it is clear
that where feedback of any kind is a possibility this must be explained clearly, and partici-
pants should be given reasonable expectations about the nature of any possible feedback
and its likely timing. Secondly, although feedback of genomic ﬁndings was not an option
in this study, participants broader views about the importance of feedback as part of the
obligations of researchers suggest that where genetic or genomic ﬁndings of direct clinical
relevance are a possibility these should be oﬀered unless there are good reasons not to
do so.
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Our observations lend support to those by other scholars such as Bredenoord, Onland-
Moret, and Van Delden (2011, p. 861) who provide similar and other grounds for the
assertion that “valid reasons exist to adopt a duty to return genetic research results… .”
Others have gone a step further by advocating a shift in the debate from whether or
not to provide individualised results to ﬁnding an acceptable compromise between the
beneﬁts and harms of disclosing the results to participants (Bredenoord, Kroes,
Cuppen, Parker, & van Delden, 2011).
Similarly, the participants’ recurrent expression of concern about their diﬃculty in pro-
curing required drug prescriptions and their appeal to the researchers for help with drug
support highlight yet another ethical gap, whereby the accepted ethical standards and
practices seem to reﬂect the notion that such support, even when it is acutely needed
by the participants, is beyond the purview of research ethics. But should the ethical prin-
ciple of beneﬁcence, which places an obligation on researchers to maximise possible
beneﬁts for research participation (Department of Health and Human Services, 1979),
not be brought to bear in this case? Thus, should support in procuring drugs, at least in
some form, not be considered a researcher’s responsibility to the participant? We
believe that these questions are legitimate and justify further consideration.
In summary, in this paper we identiﬁed a number of research practices that could be
improved upon in order for clinical research to be more responsive to research partici-
pants’ needs and contextual realities. Speciﬁcally, we suggested changes in three thematic
areas: (1) information delivery & the consenting process, (2) feedback to research partici-
pants and (3) support during and after the study.
As described, the empirical research reported in this paper forms part of a broader
project involving stakeholders in Uganda, Ghana and Zambia. Papers from Ghana and
Zambia will be published separately. The totality of our ﬁndings will be made available
to the H3Africa ethics working group to help support them in their development of a
robust and supportive ethical and governance framework for genomic research in Africa.
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